AnaptysBio
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 117
- Market Cap
- $1.1B
- Website
- http://www.anaptysbio.com
- Introduction
AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
Clinical Trials
34
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (33 trials with phase data)• Click on a phase to view related trials
A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2025-10-03
- Lead Sponsor
- AnaptysBio, Inc.
- Target Recruit Count
- 132
- Registration Number
- NCT06127043
- Locations
- 🇺🇸
AnaptysBio Investigational Site 10-115, Phoenix, Arizona, United States
🇺🇸AnaptysBio Investigational Site 10-117, Garden Grove, California, United States
🇺🇸AnaptysBio Investigational Site 10-112, Lancaster, California, United States
A Study of Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis (RENOIR)
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- AnaptysBio, Inc.
- Target Recruit Count
- 420
- Registration Number
- NCT06041269
- Locations
- 🇮🇹
AnaptysBio Investigative Site 20-106, Milan, Lombardy, Italy
🇮🇹AnaptysBio Investigative Site 20-110, Milan, Italy
🇺🇸AnaptysBio Investigative Site 10-132, Flagstaff, Arizona, United States
This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- AnaptysBio, Inc.
- Target Recruit Count
- 201
- Registration Number
- NCT05935085
- Locations
- 🇺🇸
AnaptysBio Investigative Site 10-140, Anaheim, California, United States
🇺🇸AnaptysBio Investigative Site 10-141, Cerritos, California, United States
🇺🇸AnaptysBio Investigative Site 10-121, Fountain Valley, California, United States
A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata
- Conditions
- Alopecia Areata
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- AnaptysBio, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT05205070
- Locations
- 🇺🇸
10-105, Birmingham, Alabama, United States
🇺🇸Site10-103, Encinitas, California, United States
🇺🇸Site 10-113, Northridge, California, United States
Etokimab in Adults With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- Conditions
- Chronic Rhinosinusitis
- Interventions
- First Posted Date
- 2018-08-03
- Last Posted Date
- 2022-01-24
- Lead Sponsor
- AnaptysBio, Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT03614923
- Locations
- 🇺🇸
Asthma & Allergy Institute, Little Rock, Arkansas, United States
🇺🇸Alliance Research Institute, Canoga Park, California, United States
🇺🇸DaVinci Research, Roseville, California, United States
- Prev
- 1
- 2
- Next